RecruitingPhase 2NCT06738368

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Washington
Principal Investigator
Ryan D. Cassaday, MD
Fred Hutch/University of Washington Cancer Consortium
Intervention
Asparaginase Erwinia chrysanthemi(drug)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
20262028

Study locations (1)

Collaborators

Jazz Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06738368 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials